文献速递中医儿科中药与中成药合理使用

茵栀黄颗粒联合光疗治疗新生儿病理性黄疸的疗效与安全性:更新系统评价与Meta分析

Therapeutic efficacy and safety of Yinzhihuang granules with phototherapy in neonatal pathologic jaundice: An updated systematic review and meta-analysis.
PubMed 文献 · Phytomedicine · 2022-03-16

该更新系统评价与Meta分析纳入19项随机对照试验共2221例新生儿病理性黄疸患者,评估茵栀黄颗粒联合光疗的疗效与安全性。结果显示联合治疗在降低总胆红素、直接胆红素、间接胆红素及缩短恢复和住院时间方面优于单用光疗,且不良反应发生率降低。结论认为联合治疗更有效且不增加不良反应,但受纳入研究异质性限制,需更多多中心随访试验验证。

要点

  • 茵栀黄颗粒联合光疗较单用光疗更有效降低胆红素水平。
  • 联合治疗可缩短黄疸恢复时间和住院时间。
  • 联合治疗不增加腹泻、皮疹、发热等不良反应发生率。

核心结论

  • 茵栀黄颗粒联合光疗治疗新生儿病理性黄疸比单用光疗更有效。
  • 应用茵栀黄颗粒不增加不良反应发生率。
  • 因纳入研究存在异质性,需更多多中心临床试验及随访确认结论。

研究设计与样本

  • 更新系统评价与Meta分析,检索中英文数据库至2021年11月18日,筛选茵栀黄颗粒治疗新生儿病理性黄疸的随机对照试验。
  • 共纳入19项试验、2221例病理性黄疸新生儿,采用STATA软件进行Meta分析,TSA软件对总有效率和不良反应进行试验序贯分析。

主要发现

  • 总胆红素WMD=-30.34(95%CI -35.44至-25.23,p<0.001),直接胆红素WMD=-15.03(95%CI -23.54至-6.52,p<0.001),间接胆红素WMD=-11.22(95%CI -17.50至-4.95,p<0.001),试验组均优于对照组。
  • 恢复时间WMD=-2.96(95%CI -3.92至-2.00,p<0.001),住院时间WMD=-3.83(95%CI -4.89至-2.76,p<0.001),试验组均短于对照组。
  • 肝功能指标组间差异有统计学意义。
  • 不良反应(腹泻、皮疹、发热)发生率试验组显著降低(RR=0.44,95%CI 0.33至0.59,p<0.001)。
  • 未发现发表偏倚,TSA分析验证了茵栀黄颗粒联合光疗的有效性和安全性。

临床怎么用

  • 新生儿病理性黄疸可在光疗基础上联合茵栀黄颗粒以增强退黄效果。
  • 联合用药可能缩短恢复和住院时间,且不增加腹泻、皮疹、发热等不良反应风险。
  • 临床决策需结合患儿个体情况及研究异质性,密切监测不良反应。

局限性

  • 纳入研究间存在异质性。
  • 需要更多多中心临床试验并进行随访以确认本研究发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Yinzhihuang granule, consisting of extracts of Artemisia capillaris Thunb., Gardenia jasminoides Ellis, Lonicera japonica Thunb., and Scutellaria baicalensis Georgi is a well-known traditional Chinese patent medicine for patients with liver injury in China. However, the effects and safety of its use for pathologic jaundice in newborns require further systematic evaluation. PURPOSE: To systematically evaluate the efficacy and safety of Yinzhihuang granules for the treatment of neonatal pathologic jaundice and to provide clinical evidence. METHODS: Chinese databases (China Network Knowledge Infrastructure, Wan Fang Database, and VIP Database) and English databases (PubMed, EmBase, and the Cochrane Library) were thoroughly investigated through screening randomized controlled trials on Yinzhihuang granules for neonatal pathologic jaundice from the establishment of all databases to November 18, 2021. A meta-analysis was performed for selected data using STATA software. TSA software was used for trial sequential analyses of the total effective rate and adverse reactions. RESULTS: A total of 19 trials and 2,221 newborns with pathologic jaundice were included in this study. Outcome measures of clinical efficacy in the experimental group were higher than in controls, including total bilirubin (WMD = -30.34, 95% CI = -35.44 to -25.23, p < 0.001), direct bilirubin (WMD = -15.03, 95% CI = -23.54 to -6.52, p < 0.001), indirect bilirubin (WMD = -11.22, 95% CI = -17.50 to -4.95, p < 0.001), recovery time (WMD = -2.96, 95% CI = -3.92 to -2.00, p < 0.001), hospitalization time (WMD = -3.83, 95% CI = -4.89 to -2.76, p < 0.001), and liver function indices. There were statistically significant differences between the two groups. Likewise, the incidence of adverse reactions, including diarrhea, erythra, and fever decreased remarkably in the trial group (RR = 0.44, 95% CI = 0.33 to 0.59, p < 0.001). Publication bias did not exist. We verified the efficacy and safety of Yinzhihuang granules with phototherapy for pathologic jaundice in newborns according using TSA analysis. CONCLUSION: Yinzhihuang granules with phototherapy for neonatal pathologic jaundice are more effective than phototherapy alone. The incidence of ADRs does not increase with the application of Yinzhihuang granules. Due to the heterogeneity across the included studies, additional multicenter clinical trials with follow-ups are needed to confirm our findings.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Feng Q, Huang Z, Su L, et al. Therapeutic efficacy and safety of Yinzhihuang granules with phototherapy in neonatal pathologic jaundice: An updated systematic review and meta-analysis. Phytomedicine. 2022. PMID: 35325827. doi:10.1016/j.phymed.2022.154051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。